SSRI, SNRI or Bupropion: How a First Antidepressant Is Chosen
On average, SSRIs, SNRIs and bupropion relieve depression to a broadly similar degree, so a first antidepressant is chosen less for raw strength than for fit. The largest comparison, a 2018 network meta-analysis of 522 trials, found every antidepressant studied beat placebo, with smaller and less certain differences between individual drugs. The deciding factors are usually your symptoms, the side effects you most want to avoid, your other medicines and health conditions, and how you or close relatives have responded before.
In broad terms, SSRIs are the common default, especially when anxiety is part of the picture; SNRIs are often considered when pain is also present; and bupropion is often considered when fatigue or sexual side effects are the main concern, and avoided in people with seizure risk or an eating disorder.
The three classes at a glance
| SSRIs | SNRIs | Bupropion | |
|---|---|---|---|
| Examples | Escitalopram, sertraline, fluoxetine, paroxetine, citalopram | Venlafaxine, duloxetine, desvenlafaxine | Bupropion (an NDRI; SR and XL forms) |
| Main action | Serotonin | Serotonin and norepinephrine | Thought to work through norepinephrine and dopamine |
| Anxiety disorders | Several are FDA-approved for anxiety disorders | Duloxetine and venlafaxine XR are FDA-approved for GAD | Not FDA-approved for any anxiety disorder |
| Other approved uses worth knowing | OCD, panic, PTSD and social anxiety for some drugs | Duloxetine: nerve pain, fibromyalgia, chronic musculoskeletal pain | XL form: prevention of seasonal depression |
| Sexual side effects | Common | Common | Not significantly different from placebo in a meta-analysis |
| Key cautions | Bleeding risk with NSAIDs, aspirin or blood thinners | Venlafaxine can raise blood pressure; duloxetine and liver injury | Seizure risk; contraindicated in seizure disorder and eating disorders |
What the evidence says about effectiveness
The 2018 Cipriani network meta-analysis in The Lancet included 116,477 participants with major depression and compared 21 antidepressants. All were more effective than placebo. When all trials were considered, differences between drugs were modest and most comparisons had wide uncertainty; the certainty of the evidence was rated moderate to very low.
The study also looked at acceptability, measured as people stopping treatment for any reason. Escitalopram, sertraline, citalopram, fluoxetine, vortioxetine and agomelatine were among the better tolerated, while venlafaxine and duloxetine were among those with higher dropout rates. That is one reason many prescribers start with an SSRI when there is no specific reason to choose otherwise.
In head-to-head trials only, a few drugs, including escitalopram, paroxetine, venlafaxine, mirtazapine and vortioxetine, came out somewhat more effective than others. Those head-to-head results varied more than the overall picture, and the authors cautioned that most comparisons were uncertain.
These are group averages from short-term trials. They do not tell you which drug will suit you, and a medicine that is middling on average can be the right one for a particular person.
What the evidence does not show
Several common beliefs about these medicines go further than the research does:
- That SNRIs are reliably stronger than SSRIs. In the largest network meta-analysis, differences between individual drugs were modest and mostly uncertain.
- That the right first drug can be picked in advance. Trials report group averages over weeks, not a prediction for any one person, which is why follow-up and a plan for the next step matter as much as the first choice.
- That a failed SSRI means SSRIs are wrong for you. In STAR*D, switching to sertraline after citalopram did about as well as switching to bupropion or venlafaxine.
- That bupropion treats anxiety disorders. It is not FDA-approved for any, and in depression with high anxiety SSRIs had a modest advantage in pooled trials.
Matching the medicine to your symptoms
Anxiety alongside depression
When anxiety is prominent, SSRIs and SNRIs are the usual choice, since several carry FDA approvals for anxiety disorders. A pooled analysis of 10 trials found a modest advantage for SSRIs over bupropion in depression with high anxiety, and no difference when anxiety was low or moderate. Anxiety treatment options compared covers the anxiety-specific choices.
Pain
Duloxetine is FDA-approved for diabetic nerve pain, fibromyalgia and chronic musculoskeletal pain as well as depression and GAD, which can make it a practical choice when pain and depression occur together.
Fatigue, low motivation and sexual side effects
Bupropion is thought to work through norepinephrine and dopamine rather than serotonin. In a meta-analysis of treatment-emergent sexual dysfunction, bupropion did not differ significantly from placebo, while most SSRIs and SNRIs did. For people whose depression shows up as exhaustion and slowed motivation, or who stopped an SSRI because of sexual side effects, prescribers often consider it. The site's guide to SSRI sexual side effects covers management options if you are already on an SSRI.
Seasonal pattern
Extended-release bupropion is FDA-approved to prevent seasonal depressive episodes, taken from fall through early spring.
Sleep and weight
Antidepressants differ in how they affect sleep and appetite, and the effects vary between people. Ask your prescriber what to expect from the specific drug and dose, and say at the outset if weight change or sleep disruption would be especially hard for you, since that can change the choice. The site's guides on SSRIs and insomnia and antidepressants and weight go into detail.
Beyond the three main classes
SSRIs, SNRIs and bupropion are not the only choices. Mirtazapine and vortioxetine were among the 21 antidepressants in the Cipriani analysis, and older classes such as tricyclics and MAOIs remain options for some people despite more side effects. These are more often considered when a first or second choice has not worked, or when a specific symptom or side-effect pattern points toward them. Your prescriber can explain why one might, or might not, make sense for you. Newer antidepressants compared and mirtazapine vs trazodone cover those alternatives.
A quick decision guide
The table below summarizes how the factors in this article tend to point. It is a starting point for a conversation with a prescriber, not a way to choose for yourself.
| If this matters most | Often considered | Caveat |
|---|---|---|
| Anxiety alongside depression | An SSRI or SNRI, several of which are FDA-approved for anxiety disorders | Bupropion is not FDA-approved for any anxiety disorder |
| Chronic pain | Duloxetine, approved for several pain conditions | Label advises avoiding it with substantial alcohol use or chronic liver disease |
| Avoiding sexual side effects | Bupropion | Contraindicated with a seizure disorder or current or past bulimia or anorexia, and used with caution when other seizure risk factors are present |
| Quitting smoking as well | Bupropion; the sustained-release form is FDA-approved for smoking cessation | Never combine two bupropion products |
| Winter-pattern depression | Bupropion XL, approved to prevent seasonal episodes | Light therapy is another mainstay |
| Tolerability above all | An SSRI with a good acceptability record, such as escitalopram or sertraline | Average tolerability does not predict yours |
| Cost | A generic in any of the three classes | Check your plan's formulary |
Within a class, individual drugs differ too. Sertraline vs escitalopram, fluoxetine vs sertraline and venlafaxine vs duloxetine compare the most common pairs.
Who should not take bupropion
Bupropion's label lists clear contraindications. It should not be used by people with a seizure disorder, a current or prior diagnosis of bulimia or anorexia nervosa, or who are abruptly stopping alcohol, benzodiazepines, barbiturates or antiepileptic drugs. It also must not be combined with MAOIs, or started within 14 days of one.
Seizure risk is dose-related, and the label lists other factors that raise it, including severe head injury, other medicines that lower the seizure threshold, and misuse of alcohol or stimulants. Bupropion is also not approved for bipolar depression. Be complete and honest about your history so the prescriber can weigh these risks.
Interactions and other health conditions
Many first-choice decisions are really about safety with the rest of your health. The interactions and conditions below come up often:
- Bupropion inhibits the liver enzyme CYP2D6 and can raise levels of some other drugs, including certain antidepressants, antipsychotics and the beta-blocker metoprolol.
- SSRIs and other drugs that affect serotonin reuptake increase bleeding risk, and aspirin, NSAIDs, warfarin and other blood thinners can add to it.
- Combining antidepressants with other serotonin-acting drugs or supplements, such as triptans for migraine or St. John's wort, can cause serotonin syndrome, which is rare but serious.
- Venlafaxine causes dose-related increases in blood pressure, so blood pressure is checked before and during treatment.
- Duloxetine's label advises avoiding it in people with substantial alcohol use or chronic liver disease, because of the risk of liver injury.
Bring a full list of your medicines and supplements to the appointment. How to prepare your medication history explains what to include.
Age, pregnancy and other circumstances
Children and teenagers
Fewer antidepressants are approved for young people. Fluoxetine's effectiveness for major depression was established in children and adolescents aged 8 to 18, and escitalopram is approved for major depression from age 12. Desvenlafaxine, an SNRI, is not approved for use in pediatric patients. The boxed warning on suicidal thoughts and behaviors applies with particular force at these ages, which is why close follow-up early in treatment matters. Teen depression treatment: a parent's guide covers therapy and medication for this age group.
Older adults
Two label cautions come up often after 60. Citalopram's label says doses above 40 mg a day are not recommended because of the risk of QT prolongation, a change in heart rhythm, and limits the maximum to 20 mg a day in people over 60, because higher blood levels are expected. SSRIs and SNRIs can also cause low blood sodium (hyponatremia), and elderly patients may be at greater risk, as may people taking diuretics. Doses are always set by the prescriber; the point is that age changes which drug and dose make sense.
Planning a pregnancy
Paroxetine's label states that, based on meta-analyses of epidemiological studies, first-trimester exposure is associated with a less than 2-fold increase in the rate of cardiovascular malformations, and that for women who intend to become pregnant or are in the first trimester it should be started only after considering other options. That is one reason pregnancy plans belong in the first conversation about choosing an antidepressant. Decisions in pregnancy weigh medication risks against the risks of untreated depression; psychiatric medications during pregnancy explains how that weighing is done.
Eating disorders
Bupropion is contraindicated with a current or prior diagnosis of bulimia or anorexia nervosa, while fluoxetine is FDA-approved to treat binge-eating and vomiting behaviors in moderate to severe bulimia nervosa. If you have any eating disorder history, say so before a first choice is made.
Weight
Concern about weight gain is one of the most common reasons people hesitate to start an antidepressant. In bupropion XL's seasonal depression trials, which lasted up to 6 months, 23% of people taking bupropion lost 5 pounds or more, compared with 11% on placebo. That is not a reason to take it for weight loss, and it is not suitable for everyone, but it is one reason prescribers consider it when weight gain would be a serious problem.
How you process medications
Genes that affect liver enzymes can change drug levels. Citalopram's label, for example, limits the maximum dose for people who are CYP2C19 poor metabolizers or who take a CYP2C19 inhibitor. Genetic testing can supply that kind of information, but it does not choose an antidepressant on its own; pharmacogenomic testing: coverage, limits and when it helps explains what it can and cannot do.
Your history, and your family's
If a particular antidepressant worked well for you before, it is usually a strong candidate again. If one caused side effects you could not tolerate, that narrows the field. Many prescribers also ask how close relatives responded to specific antidepressants, as one more clue alongside your own history.
Useful things to tell the prescriber at the first visit:
- Every antidepressant you have taken, the highest dose, how long, and why it stopped.
- Any history of seizures, head injury, eating disorders, high blood pressure, liver disease or bleeding problems.
- Any periods of unusually high energy, little need for sleep or impulsive behavior, and any family history of bipolar disorder.
- Alcohol and other substance use, and every medicine and supplement you take.
- Pregnancy, breastfeeding or plans to become pregnant.
Cost and access matter too. Ask about generic options and whether a drug is on your plan's formulary, because a medicine you cannot afford to refill is not a good choice however well it fits on paper.
How the first weeks usually go
Common early side effects of SSRIs and similar antidepressants include upset stomach, headache and sexual changes. They are generally mild and often fade with time, and starting at a low dose and increasing slowly can help people who are sensitive to them. Sleep, appetite, energy and concentration often improve before mood does.
NICE recommends a first review usually within two weeks of starting, or within one week for people aged 18 to 25 or when there is a particular concern about suicide risk. Use that visit to report side effects honestly, including ones that feel awkward to mention. Some people notice a flattening of emotions on SSRIs; the site's guide to emotional blunting explains what can be done about it.
If the first choice does not work
Many people need more than one try, and that is expected rather than a sign of failure. In the STAR*D trial, 727 adults whose depression had not remitted on citalopram, or who could not tolerate it, were randomly switched to bupropion SR, sertraline or venlafaxine XR. About one in four reached remission after the switch, and the three medicines did not differ significantly in outcomes, tolerability or adverse events; the authors concluded that any of them was a reasonable second step.
That finding has a practical meaning: after a first SSRI does not work, switching within the class, to an SNRI or to bupropion are all defensible, and the choice can again follow your symptoms and side effects. NICE lists options that include increasing the dose, switching to another medication in the same class or a different class, switching to or adding a psychological therapy, and adding a group exercise program. Switching may require cross-tapering, which your prescriber plans. Switching antidepressants describes what that looks like, and antidepressant augmentation covers adding a second medicine instead.
How long treatment usually lasts
Once an antidepressant has worked, stopping as soon as you feel better is a common mistake. NICE advises that treatment might need to continue for at least 6 months after symptoms remit, with regular reviews. When it is time to stop, the dose is usually reduced in stages rather than all at once. Fluoxetine is a partial exception in practice: its label notes that because of the long elimination half-lives of the drug and its active metabolite, dose changes are not fully reflected in the blood for several weeks, which affects both dose adjustment and stopping.
Cost, generics and access
Most SSRIs, the common SNRIs and bupropion are available as generics. FDA states that an approved generic has the same active ingredient, strength, dosage form and route as the brand, is bioequivalent to it, and provides the same clinical benefit and risks. If a refill from a different manufacturer seems to work differently, tell your prescriber and pharmacist rather than adjusting it yourself. Generic vs brand-name psychiatric medications and lowering prescription costs cover the details.
Questions to ask before you start
Current guidelines emphasize shared decision-making that reflects your values, preferences and treatment history; the 2023 Canadian CANMAT depression guidelines, for example, are built around that personalized approach. These questions help you take part:
- Why this medicine for me, rather than the other two classes?
- Which side effects are most likely in the first two weeks, and which should make me call?
- Does it interact with anything I take, including supplements, migraine medicine or blood thinners?
- When will we judge whether it is working, and what will we use to measure that?
- If it does not work, what is the next step?
- Is a generic available, and is it on my plan's formulary?
Safety points that apply to every option
All antidepressants carry an FDA boxed warning: in short-term trials, they increased the risk of suicidal thoughts and behaviors in children, adolescents and young adults aged 18 to 24, though not in adults over 24. Anyone starting an antidepressant should be monitored for worsening mood and for new anxiety, agitation, insomnia, irritability, restlessness or unusually high energy, and should report these promptly.
Labels also ask prescribers to screen for bipolar disorder before starting, because antidepressants can trigger mania or hypomania in people at risk. And when it is time to stop, a gradual taper is recommended over abrupt stopping, to reduce discontinuation symptoms. Never stop or switch on your own; plan any change with your prescriber.
Antidepressants usually take four to eight weeks to work. If the first one does not help enough, the next steps are covered in what a psychiatrist considers when antidepressants haven't worked, and the site's guide to SSRI side effects explains which early effects tend to fade.
If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.
At this practice, antidepressants are prescribed within psychiatric evaluation and medication management, which can be combined with psychotherapy, lab testing, and nutrition and lifestyle psychiatry. If you are deciding who should manage your prescription, psychiatrist or primary care lays out the options, and the Choosing Psychiatric Care guide explains how to start.
Frequently asked questions
Is an SNRI stronger than an SSRI?
Not reliably. In the largest network meta-analysis, differences between individual antidepressants were modest and uncertain, and some SNRIs had higher dropout rates. The better choice depends on your symptoms and side-effect profile.
Can bupropion be taken with an SSRI?
Prescribers sometimes combine them, but bupropion raises levels of some SSRIs through CYP2D6 inhibition, so doses and side effects need monitoring. This is a decision for your prescriber.
Does bupropion help anxiety?
It is not FDA-approved for anxiety disorders. In depression with high anxiety, SSRIs showed a modest advantage in pooled trials.
How long should I give a first antidepressant?
Usually four to eight weeks at an adequate dose before judging it, with earlier check-ins for side effects and safety.
Can a genetic test pick my antidepressant?
Genetic testing can add information about how you process some drugs, but it does not replace a clinical evaluation. The site has a guide to genetic testing for psychiatric medication.
Does the time of year matter for bupropion XL?
For people with winter-pattern depression, bupropion XL is FDA-approved to prevent seasonal episodes, taken from fall through early spring. See seasonal affective disorder treatment options for how it compares with light therapy.
Is it a bad sign if I need to switch?
No. In a large trial of people whose first SSRI did not work or was not tolerated, about one in four reached remission after switching to bupropion, sertraline or venlafaxine, with no significant difference between the three.
Can I switch from brand to generic?
Usually, yes. FDA says approved generics have the same active ingredient and provide the same clinical benefit and risks. Tell your prescriber if a refill from a different manufacturer seems to work differently.
Sources
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet (Cipriani et al.), 2018. pubmed.ncbi.nlm.nih.gov
- Duloxetine delayed-release capsules prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology (Serretti and Chiesa), 2009. pubmed.ncbi.nlm.nih.gov
- Wellbutrin XL (bupropion extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Mental Health Medications. National Institute of Mental Health, 2023. nimh.nih.gov
- Lexapro (escitalopram) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
- Paxil (paroxetine) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- Effexor XR (venlafaxine extended-release) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Journal of Clinical Psychiatry (Papakostas et al.), 2008. pubmed.ncbi.nlm.nih.gov
- Seasonal Affective Disorder. National Institute of Mental Health, 2023. nimh.nih.gov
- Depression in adults: treatment and management (NG222), Recommendations. National Institute for Health and Care Excellence, 2022. nice.org.uk
- PRISTIQ (desvenlafaxine) extended-release tablets prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- PROZAC (fluoxetine) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
- CELEXA (citalopram) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
- Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine (Rush AJ et al., STAR*D), 2006. pubmed.ncbi.nlm.nih.gov
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry (Lam RW et al.), 2024. pubmed.ncbi.nlm.nih.gov
- Generic Drug Facts. U.S. Food and Drug Administration, 2026. fda.gov
Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel